Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRLM.L Regulatory News (RLM)

  • There is currently no data for RLM

Director Dealing

2 Apr 2015 07:00

RNS Number : 2552J
PuriCore Plc
02 April 2015
Β 

ο»Ώ

PuriCore plc ("PuriCore" or the "Company")

Β 

Director Dealing

Β 

2 April 2015 - PuriCore plc (AIM: PURI), an international company focused on safe and effective protection against the spread of infectious pathogens, today announces a director dealing, in accordance with the Disclosure and Transparency Rules. On 1 April 2015, the following Director notified the Company that he had purchased ordinary shares of 10p each in the share capital of the Company ("Shares"), as set out below.

Β 

Β 

Β 

Name

Date purchased

Number of Shares purchased

Purchase price of Shares

Shareholding following the acquisition

% of issued share capital

Charles SpicerNon-Executive Chairman

1 Apr 2014

Β 

50,610

Β 

32p

Β 

75,000

Β 

0.15%

Β 

Β 

-Ends-

Β 

Enquiries:

Β 

PuriCore plc

+44 (0) 20 3727 1000

Michael Ashton, Chief Executive Officer

Marella Thorell, Chief Financial Officer and Chief Operating Officer

FTI Consulting

+44 (0) 20 3727 1000

Simon Conway / Mo Noonan / Victoria Foster Mitchell

N+1 Singer (Nominated Adviser & Broker)

+44 (0) 20 7496 3000

Aubrey Powell / Jen Boorer / Thomas Smale

Β 

Β 

About PuriCore

PuriCore is an international company focused on developing and commercialising safe and effective products to protect against the spread of infectious pathogens based on its proprietary hypochlorous acid platform technology. Its products are currently used in two broad market segments: Supermarket Retail and Health Sciences. PuriCore's products do not cause harm to human or animal life or to the environment.

Β 

In the Supermarket Retail segment, PuriCore offers products to US retailers for use in their fresh produce departments to improve food safety and quality, to extend shelf life and to decrease food wastage. Our product is an eco-friendly, food-safe sanitising solution at a neutral PH that is used to protect produce from cross contamination and improve freshness. Our Sterilox Fresh Systems are capital equipment that are installed at customer locations and allow for generation of solution as needed at the store. ProduceFresh is our concentrate bottled version providing the same levels of stability, freshness and quality in a convenient consumable package. Additionally, the Company's FloraFresh products, also sold as a concentrate in bottled form, protect against fungal growth and extend the life of cut flowers, with an initial focus on supermarket floral departments.

Β 

In Health Sciences, PuriCore's Wound Care business provides products that are used to treat chronic and acute wounds, including diabetic ulcers and burns in humans. A range of products have also been developed to manage wounds in companion and farm animals. The Company's Dermatology business is currently focused on treatments for atopic dermatitis. PuriCore is headquartered in Malvern, Pennsylvania.

This information is provided by RNS
The company news service from the London Stock Exchange
Β 
END
Β 
Β 
RDSUGUQGCUPAPPG
Date   Source Headline
4th Jun 20144:46 pmRNSPublication of Circular
4th Jun 20147:00 amRNSSale of Endoscopy Business
14th May 20147:00 amRNSInterim Management Statement
24th Apr 20147:00 amRNSFinal Results
10th Apr 20147:00 amRNSNotice of Results
19th Feb 201411:22 amRNSBlocklisting Interim Review
18th Feb 20147:00 amRNSTrading Statement
13th Feb 20147:00 amRNSMiddle East Wound Care Marketing Agreement
7th Nov 20137:00 amRNSRe Agreement
6th Nov 20138:50 amRNSHolding(s) in Company
4th Nov 201310:03 amRNSHolding(s) in Company
1st Nov 20137:00 amRNSDirector/PDMR Shareholding
28th Oct 20137:00 amRNSInterim Management Statement
22nd Oct 20137:00 amRNSLaunches New Animal Health Wound Product NovaZo
15th Oct 20137:00 amRNSDirector Details
11th Oct 20137:00 amRNSReached agreement with Misonix
27th Sep 20137:00 amRNSValue Creation Plan Update
6th Sep 20131:58 pmRNSDirector Dealing
16th Aug 20133:24 pmRNSDirector Dealing
12th Aug 20131:59 pmRNSShare Option Grant
8th Aug 20137:00 amRNSHalf Yearly Report
2nd Aug 20137:00 amRNSBlocklisting Interim Review
17th Jul 20137:00 amRNSNotice of Results
28th Jun 20137:00 amRNSTotal Voting Rights
26th Jun 201311:19 amRNSResult of AGM
20th Jun 20137:00 amRNSPuriCore signs $13.5 million US deal
19th Jun 20131:16 pmRNSAGM Update
11th Jun 20133:08 pmRNSHolding(s) in Company
11th Jun 20133:06 pmRNSHolding(s) in Company
5th Jun 20131:13 pmRNSHolding(s) in Company - Replacement
5th Jun 20131:10 pmRNSHolding(s) in Company - Replacement
4th Jun 20133:04 pmRNSHolding(s) in Company
4th Jun 20133:01 pmRNSHolding(s) in Company
17th May 20137:46 amRNSInterim Management Statement
14th May 20137:00 amRNSBoard Changes
2nd May 20137:00 amRNSShare Option Grant
1st May 20137:00 amRNSTotal Voting Rights
30th Apr 20137:00 amRNSFinal Results
17th Apr 20131:57 pmRNSNotice of Results
8th Apr 20137:00 amRNSPuriCore Signs Major US Deal
3rd Apr 20137:00 amRNSPuriCore Signs Vashe Marketing Agreement
7th Mar 20137:00 amRNSTrading Update
6th Mar 20137:00 amRNSPuriCore Partners with Onset Dermatologics
5th Mar 20137:00 amRNSBoard and Organisational Changes
15th Feb 20135:20 pmRNSBlocklisting Interim Review
14th Feb 20137:00 amRNSFDA 510(k) Clearance
12th Feb 20136:01 pmRNSShare Option Grant and Blocklisting Update
7th Feb 20135:39 pmRNSApplication for Blocklisting
1st Feb 20134:40 pmRNSSecond Price Monitoring Extn
1st Feb 20134:35 pmRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.